KYMR — Kymera Therapeutics, Inc.

Is KYMR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of November 17, 2026

Kymera Therapeutics, Inc. (KYMR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $125.85. The rating moved from Overbought to Neutral on November 12, 2026.

AI analysis

Kymera Therapeutics, Inc. (KYMR) is an early-to-mid stage biotech with a targeted protein degradation platform and multiple programs that create asymmetric upside from clinical or partnership news. Key vulnerabilities include binary clinical outcomes, the likelihood of future financing needs, and high valuation sensitivity to news flow; downside scenarios are driven by program failures or delays while upside is tied to successful data and deal activity.

Key factors

  • Differentiated targeted protein degradation (TPD) platform with multiple discovery-stage and clinical-stage programs providing high upside from positive data readouts or partnerships
  • Sector thematic tailwinds toward specialty franchises and distributor/service providers that could favor partnerships or commercial pathways for TPD assets
  • Potential M&A or collaboration interest from large-cap pharma actively consolidating specialty franchises, which could create strategic exit or licensing opportunities
  • Limited near-term macro volatility and measured risk-on tone in markets, supporting sentiment for selective biotech upside
  • Clinical catalysts and potential data readouts over the next 1–6 months that can materially reprice the equity if positive

Risks

  • Clinical trial failures or disappointing data for lead programs, which would materially reduce valuation
  • Regulatory setbacks or longer-than-expected approval timelines for novel modality programs such as protein degraders
  • High cash burn typical of clinical-stage biotech and potential need for dilutive financing if partnerships or milestone payments are delayed
  • Competitive pressure from larger pharma investments in adjacent modalities (e.g., small molecules, biologics, GLP‑1/amylin combinations) and alternative therapeutic approaches
  • Market illiquidity and elevated share-price volatility common to small/clinical-stage biotech names
  • Broader policy or payer risk (e.g., reimbursement challenges) and sector-level regulatory/antitrust scrutiny that can indirectly affect deal-making and pricing environment

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for KYMR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.